Ileal bypass for hyperlipidemia

Henry Buchwald, Laurie Fitch, Richard L. Varco

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Partial ileal bypass (PIB) is a safe, effective, and lasting therapy for the reduction of lipids and lipoproteins in patients with hyperlipidemia. Following PIB, circulating plasma and low-density lipoprotein (LDL) cholesterol fall markedly, while high-density lipoprotein (HDL) cholesterol rises. The average plasma cholesterol lowering is 25% after diet, with a 40% reduction in the LDL-cholesterol fraction; concurrently, the HDL-cholesterol rises about 8%. These effects have been demonstrated to be maintained for up to 20 years. Currently, PIB is being used in the Program on the Surgical Control of the Hyperlipidemias (POSCH), a randomized controlled clinical trial designed to assess the effects of lipid reduction on mortality and morbidity in a postmyocardial infarction population with arteriographically demonstrated coronary atherosclerosis.

Original languageEnglish (US)
Pages (from-to)850-859
Number of pages10
JournalWorld Journal of Surgery
Volume9
Issue number6
DOIs
StatePublished - Dec 1 1985

Fingerprint Dive into the research topics of 'Ileal bypass for hyperlipidemia'. Together they form a unique fingerprint.

Cite this